conclusion
This study reports a case of sunitinib-induced TMA diagnosed based on
clinical presentation and response to treatment. Sunitinib-induced TMA
is an uncommon adverse effect of sunitinib therapy, But it can be
deadly. Due to the increasing use of this drug in cancer treatment,
Oncologists should be aware of life-threatening thromboembolic events
associated with sunitinib so that prompt and appropriate intervention
can be undertaken.